FOMDWebPartPage

Surgical Oncology

Norman Kneteman

Adjunct Professor
Surgical Oncology
2D4.44 WCM
University of Alberta Hospital
8440 - 112 Street NW
Edmonton, Alberta T6G 2B7
Tel: 780.407.7072

Profile

Training  

Dr. Norman Kneteman trained in Surgery at the University of Alberta and completed his Transplant Fellowship and post-graduate training in islet transplantation at Washington University School of Medicine St. Louis. Dr. Kneteman currently holds a Senior Scholarship from the Alberta Heritage Foundation for Medical Research and a Canadian Institutes for Health Research/Wyeth Canada Research Chair in Transplantation.
 

 

Research Interests 
  • clinical studies in immunosuppression
  • liver transplantation
  • basic studies and translational research on hepatitis C with the chimeric humanized mouse liver model of hepatitis C virus infection.

 

Publications

2006
 
Cantarovich M, Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Peltekian K, Barkun J. “Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients”. Transplantation. 2006 Aug 15;82(3):433-6.
 
Johnston ST, Blitz M, Kneteman NM and Bigam D. Combined Hepatic and Inferior Vena Cava Resection for Colorectal Metastases. Journal of Gastrointestinal Surgery. 10(2):220-226, 2006.
 
Kneteman NM, Weiner A, Mercer DF, Aukerman L, Kovelesky R,  Ni ZJ, Zhu Q, Kline J, Gao T, Hsi B, Schiller D, Douglas D, Addison W, Tyrrell DLJ.  Anti-HCV Therapies in Chimeric scid-Alb/uPA Mice Parallel Outcomes in Human Clinical Application. Hepatology. 2006 Jun;43(6):1346-53.
 

Sacci, JB Jr, Alam U, Douglas D, Lewis J, Tyrrell DLJ, Azad AF, Kneteman NM.  Plasmodium falciparum infection and exoerythrocytic development in mice containing chimeric human livers. Int J for Parasitol 2006 Mar;36(3):353-360.

Walters K, Joyce MA, Thompson JC, Smith MW, Yeh MM, Proll S, Zhu LF, Gao TJ, Kneteman NM, Tyrrell DLJ, Katze MG. Host-specific Response to HCV Infection in the Chimeric SCID/Alb-uPA Mouse Model: Role of the Innate Antiviral Immune Response. PLoS Pathog. 2006 Jun;2(6) e59.

Walters K, Joyce MA, Thompson JC, Proll S, Wallace J, Smith MW, Furlong J, Kneteman NM, Tyrrell DLJ, Katze MG. Application of functional genomics to the chimeric mouse model of HCV infection: optimization of microarray protocols and gonomics analysis. Virology Journal 2006, 3:37 (25 May 2006).
 
Roy A, Kneteman NM, Lilly L, Marotta P, Peltekian K, Scudamore C, Tchervekov J.  Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplantation.  Transplantation, 2006 Aug 27 82(4):494-500.
 

Toso C, Kneteman N. Does mycophenolate mofetil reduce the risk of late acute rejection after liver transplantation? Nature Clin Pract: Gastroenterol & Hepatol. 2006 Dec  3 (12)664-665.

2007

Toso C, Meeberg G, Bigam D, Oberholzer J, Shapiro AMJ, Gutfreund K, Ma MM, Mason A, Wong W, Bain V, Kneteman N. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects. Transplantation. May 2007 83(9):1162-8.

Toso C, Al-Qahtani M, Al Saif FA, Bigam DL, Meeberg G, Shapiro AMJ, Bain V,  Kneteman NM. ABO-Incompatible liver transplantation for critically ill patients. Transplant Int. 2007 Aug 20(8):  675-81.
 

Song JH., Tse MCL, Bellail A, Phuphanich S, Khuri F, Kneteman NM, Hao C.  Lipid rafts and non-rafts mediate tumor necrosis factor related apoptosis-inducing ligend induced apoptotic and non-apoptotic signals in non-small cell lung carcinoma cells.  Cancer Res, 2007July 67(14):6946-55.

Wang P, Zhang J, Bellail A, Jiang W, Hugh J, Kneteman NM, Hao C. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal. 2007 Jun 21 19(11) 2237-46.
 
Campbell PM, Senior PA, Salam A, LaBranche K, Bigam DL, Kneteman NM, Imes S, Halpin A, Ryan EA, Shapiro AMJ. High Risk of Sensitization after Failed Islet Transplantation. Am J Transplant  2007, Oct 7, 7(10) 2311-2317.
 
Lakey JR, Kin T, Warnock GL, Shapiro AM, Tsapogas P, Imes S, Korbutt GS, Kneteman NM, Rajotte RV, Ryan EA.  Long-term graft function after allogeneic islet transplantation.  Cell Transplant 2007 16(4) 441-446.
 
Kneteman N., Toso C. Atlas of Organ Transplantation by A. Humar, J. Matas, WD. Payne. American Journal of Transplanation. 7 (6) 1680. June 2007.
 
2008
 
Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR.  Broadly neutralizing human monoclonal antibodies protect against challenge with hepatitis C virus quasispecies in vivo.  Nature Medicine 2008 Jan;14(1) 25-7. 
 
Toso C, Wei A, Trotter J, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AMJ, Kneteman NM.  Total tumor volume predicts risk of reoccurance following liver transplantation in patients with hepatocellular carcinoma.  Liver Transplantation. 2008 Aug;14(8): 1107-15.
 
Beleid R, Douglas D, Kneteman N, Kaur K. Helical Peptides Derived from Lactoferrin Bind Hepatitis C Virus Envelope Protein E2. Chemical Biology & Drug Design. 2008 Nov,72(5): 436-443.
 
Laporte MG, Jackson RW, Draper TL, Gaboury JA, Galie K, Herbertz T, Hussey AR, Rippin Sr, Benetatos CA, Chunduru SK, Christensen JS, Coburn GA, Rizzo CJ, Rhodes G, O’Connell J, Howe AY, Mansour TS, Collett MS, Pevear DC, Young DC, Gao T, Tyrrell DL, Kneteman NM, Burns CJ, Condon SM. The discovery of pyrano[3,4-b]indole-based allosteric inhibirots of HCV NS5B polymerase with in vivo activiey. Chem. Med. Chem. 2008 Oct;3(10):1508-15.
 
Alsobaibani F, Bigam D, Kneteman N, Shapiro AJ, Sandha GS. The Impact of Peroperative Endoscopic Ultrasound on the Surgical Management of Pancreatic Neuroendocrine Tumours. Can J. Gastroenterol. 2008 Oct; 22(10):817-20.
 
Ng VL, Fecteau A, Shepherd R, Magee J, Bucuvalas J, Alonso E, McDiarmid S, Cohen G, Anand R, …..Kneteman NM. Outcomes of 5-Years Suviors of Pediatric Liver Transplantation: Report on 461 Children From a North American Multicenter Registry. Pediatrics. Dec;122(6):e1128-35.
 
Cadili A, Kneteman N. The Role of Macrophages in Xenograft rejection. Transplant Proc. 2008 Dec;40(10): 3289-93. Review.

 

2009
 
Kneteman NM, Toso C. In vivo study of HCV in mice with chimeric human livers. Methods Mol. Biol. 2009; 510: 383-99.
 
Wang P, Lo A, Young JB, Song J, Lai R, Kneteman N, Hao C, Li L. Targeted Quantitative Mass Spectrometric Indntification of Differentially Expressed Proteins between Bax-Expressing and Deficient Colorectal Carcinoma Cells. Jour. Prote Res. 2009 Jul;8(7):3403-14.  E-pub 2009 May 08.
 
Joyce MA, Walters K, Lamb S, Zhu L, Yeh MM, Kneteman N, Doyle JS, Katze MG, Tyrrell DL. HCV induces oxidative and ER Stress, and Sensitizes Infected Cells to Apoptosis in SCID/Alb-uPA mice. Plos Pathogens. 2009 Feb;5(2):e1000291. Epub 2009 Feb 6.
 
Asthana S, Kneteman N. Operating On A Patient With Hepatitis C. 2009 Can J Surg, Vol 52, No. 4, 337-341.
 
Toso C, Kneteman N, Shaprio AMJ, Bigam D. The Estimated Number of Patients with Hepatocellular Carcinoma Slected for Liver Transplantation Using Expanded Selection Criteria. Transpl Int. 2009; 22(9):869-75  2009 Apr 06 [Epub ahead of print].
 
Toso C, Asthana S, Bigam D, Shapiro AMJ, Kneteman NM. Re-assessing selection criteria prior to liver transplantation for hepatocellular carcinoma using the SRTR database. Hepatology. 2009 Mar;49(3):832-8. Published on-line Nov. 13, 2008.
 
Kneteman NM, Howe AYM, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DLJ, Immermann F, Chaudhary I, Speth J, Villano SA, O’Connell J, Collett M.  HCV796: a selective NS5B polymerase inhibitor with potent antiHCV activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology. 2009 Mar;49(3):745-52 Published online 2008 Nov 05.
 
VanBuskirk K, de la Vega P, Maier A, O’Neill M, Krzych U, Williams J, Dowler M, Sacci J Jr, Kangwanrangsan N, Tsuboi T, Kneteman N, Heppner G, Aly A, Cowman A, Kappe S. Preerythrocytic,  live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA.  Aug 4;106(31):13004-9. 2009 July 22. E-pub July 22, 2009.
 
Montano-Loza A, Tandon P, Kneteman N, Bailey R, Bain V. Rotterdam Score Discriminates Early Mortality and Surgical Shunting Prolng Transplant-Free Survival in Budd-Chiari Syndrome. Accepted. Alimentary Pharmacology & Therapeutics, 2009 September 01 [Epub ahead of print].
 
2010
 
Molinari M, Berman K, Meeberg G, Shapiro AMJ, Bigam D, Trotter JF, Kneteman N. Multicentric Outcome Analysis of Sirolimus Based Immunosuppression in 252 Cadaveric Liver Transplant Patients. Transpl Int. 2010 Feb;23(2):155-68. 2009  Sep 18. [Epub ahead of print].
 
Asthana S, Maguire C, Lou L, Meier M, Bain V, Townsend R, Lien D, Bigam D, Kneteman N, Shapiro AM. Successful resolution of severe hepatopulmonary syndrome following liver transplantation. Transpl Int. 2010 Apr 1;23(4):432-5. 2009 Nov 18 [Epub ahead of print].
 
Toso C, Patel S, Asthana S, Kawahara T, Girgis S, Kneteman N, Shapiro AMJ, Bigam D. The impact of sirolimus on hepatocyte proliferation after living donor liver transplantation. Clinical Transplantation  2010 September/October; 24( 5),: 695–700, 9 Dec 2009 [Epub ahead of print].
 
Emamaulle JA, Edgar R, Toso C., Thiesen A, Bain V, Bigam D, Kneteman N, Shapiro AM. Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management. Liver Transpl. 2010 Feb;16(2):191-7.
 
Kawahara T, Douglas D. Lewis J, Addison W, Churchill T, Kneteman NM.  Critical role of NK cels in the rejection of transplanted human hepatocyte transplantation into SCID/Alb-uPA mice. Transplant Int. 2010 Feb 17 [Epub ahead of print].
 
Douglas D, Kawahara T, Bond D, Fischer KP, Lewis J, Kneteman NM. Therapeutic Efficacy of Human Hepatocyte Transplantation in a SCID/UPa Mouse Model with Inductible Liver Disease.  PLos ONE. 2010 Feb;5(2): e9209.
 
Toso C, Mentha G, Kneteman NM, Majino P. The Place of Dowstaging for Hepatocellular Carcinoma. J Hepatology 2010  Jun;52(6):930-6.  Epub 2010 March 15.
 
Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular cardinoma. Hepatology. 2010 April; Vol 51(4): 1237-43. 2009 Nov 13. Epub ahead of print.
 
Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, ….Geissler EK. A prespective randomized open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular cardinoma. BMC Cancer 2010 May 11;10(1): 190. [Epub ahead of print].
 
Steenbergen RH, Joyce MA, Lund G, Lewis J, Chen R, Barsby N, Douglas D, Zhu LF, Tyrrell L, Kneteman NM. Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success.Am J Physiol Gastrointest Liver Physiol. 2010 299;G844-G854. Epub ahead of print July 22, 2010.
 
Allam N, Al Saghier M, El Sheikh Y, Al Sofayan M, Khalof  H, Al Sebayel M, Halemy A, Kamel Y, Al Jedai A, Abdel-Dayem H, Kneteman NM, Al Saghier A, Al Hamoudi W, Abdo AA. Clinical Outcomes for Saudi and Egyptian Patients Receiving Deceased Donor Liver Transplantation in China. Americian Journal of Transplantation 2010, 10:1834-1841.
 
Kawahara T, Toso C, Douglas D, Nourbakhsa M, Lewis J, Tyrrell DL, Lund G, Churchill TA, Kneteman NM. Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl. 2010 Aug;16(8):974-82.
 
Trunecka P, Boillot O, Seehofer D, Pinna AD, Ericzon B-G, ……., Kneteman NM, et al. Once-Daily Prolonged-Release Tacrolimus (ADVAGRAF) Versus Twice-Daily Tacrolimus (PROGFAF) in Liver Transplantation. Americian Journal of Transplantaton 2010; 10(10):2313-23. Epub 2010 Sept 14.
Kneteman NM, Kawahara T. Reply. Liver Transplantation 2010 Dec;16(12):1445.
 
Burak K, Kneteman N. An Evidence-Based Mulitdisciplinary Approach to the Management of Hepatocelllar Carcinoma (HCC): The Alberta HCC Algorithm. The Canadian Journal of Gasterentology. 2010 Nov;24(11):643-50.
 
Mohajerani SA, Nourbakhsh M, Cadili A, Lakey JRT, Kneteman NM.  Transplant of Primary Human Hepaticytes Co-Cultured with Bone Marrow Stromal Cells to SCID Alb-uPA Mice. Cell Medicine: Part B of Cell Transplantation 2010 Vol 1:81-92.
 
Asthana S, Maguire C, Lou L, Meier M, Bain V, Townsend R, Lein D, Bigam D, Kneteman N, Shapiro AMJ. Successful resolution of severe hepatopulmonary syndrome following liver transplantation. Transplant International 2010 23:432-35.
 
2011
 
Merani S, Majno P, Kneteman N, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011 Feb 17[Epub ahead of print].
 
Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, Kneteman N, Mills E. Liver tranpslatn outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS 2011 Mar27:25(6):777-787.
 
Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro AMJ, Kneteman NM. The impact of sirolimus on Hepatitis C recurrence after liver transplantation. Can J Gastroenterol.  2011 Jan;25(1):28-34.
 
Kawahara T, Asthana S, Kneteman NM. M-TOR Inhibitors: What Role in Liver Transplantation?  Journal of Hepatology 2011 July 19 [Epub ahead of print].
 
Kneteman NM, Lewis J, Dibben C, Douglas D, Nourbakhsh M, Tyrrell DL, Lund G. The Impact of Calcineurin Inhibitors on HCV replication in a Chimeric Mouse model of HCV Infection. Liver Transplantation 2011 Aug 11.[Epub ahead of print].
 
Kawahara T, Kin T, Kashkoush S, Gala Lopez B, Bigam DL, Kneteman NM, Koh A, Senior PA, Shapiro AMJ. Protal Vein Thrombosis in a Potentially Preventable Complication in Clinical Islet Transplantaiton. American Journal of Transplantation. 29 August 2011 [E-pub ahead of print].
 
Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R. Transarterial chemoemboilizaton in patients with hepatocellular carcinoma: Predictors of survival. Can J Gastroenterol 2011 Aug;25(8):436-32.